Product image of Letrozol Aristo (Letrozole) supplied by GNH India

Letrozol Aristo

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Aristo (Letrozole)

Letrozole, the active ingredient in Letrozol Aristo, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer.

GNH India supplies Letrozol Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aristo Pharma Gmbh (Art 57)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in the management of hormone‑dependent breast cancer in postmenopausal women.

  • Postmenopausal estrogen receptor‑positive breast cancer (adjuvant): reduces recurrence risk after surgery.
  • Postmenopausal estrogen receptor‑positive breast cancer (neoadjuvant): shrinks tumor before surgery.
  • Metastatic estrogen receptor‑positive breast cancer in postmenopausal women: slows disease progression.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme, a cytochrome P450 isoform responsible for converting androstenedione and testosterone into estrone and estradiol. By inhibiting this enzyme, letrozole markedly lowers peripheral estrogen synthesis, depriving estrogen‑dependent tumor cells of a growth stimulus. The reduction in circulating estrogen levels is sustained, leading to inhibition of tumor proliferation in hormone‑sensitive breast cancer.

Side Effects

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Hot flashes: sudden feeling of warmth, often with sweating.
  • Arthralgia: joint pain or stiffness.
  • Fatigue: persistent tiredness not relieved by rest.
  • Nausea: upset stomach, sometimes with vomiting.
  • Headache: mild to moderate pain in the head.
  • Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

  • Severe liver injury: elevated enzymes, jaundice, hepatic failure.
  • Osteoporotic fractures: increased risk of bone breaks due to reduced bone density.
  • Pulmonary embolism: blockage of lung arteries, presenting with sudden breathlessness.
  • Myocardial infarction: heart attack, chest pain, and related symptoms.
  • Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise.
  • Elevated cholesterol leading to cardiovascular events: significant rise in LDL cholesterol.

Precautions & Warnings

When prescribing letrozole, clinicians should observe several precautionary measures to minimize risk.

  • Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation.
  • Liver function monitoring: perform periodic liver enzyme tests.
  • Lipid profile monitoring: check cholesterol levels regularly.
  • Avoid use in premenopausal women: efficacy is limited and may cause ovarian stimulation.
  • Concomitant estrogen therapy: discontinue hormonal replacement that may counteract drug effect.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma concentrations.
  • Estrogen‑containing hormone therapy (e.g., oral contraceptives, HRT): antagonizes therapeutic effect.
  • Cholestyramine or other bile‑acid sequestrants: decrease absorption of letrozole.

Moderate Interactions (Monitor Closely)

  • CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole levels.
  • Anticoagulants (e.g., warfarin): potential alteration of INR, monitor coagulation.
  • SSRIs and SNRIs: may affect platelet function, observe bleeding risk.
  • Glucocorticoids: may increase risk of bone loss, monitor bone health.

Frequently Asked Questions

Letrozol Aristo contains letrozole, an aromatase inhibitor indicated for the treatment of postmenopausal women with estrogen receptor‑positive breast cancer. It is employed in adjuvant, neoadjuvant, and metastatic settings to reduce estrogen‑driven tumor growth.

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By reversibly inhibiting this enzyme, the drug sharply lowers circulating estrogen levels, depriving hormone‑sensitive breast cancer cells of the estrogen needed for proliferation.

The dose of Letrozol Aristo is determined by the prescribing clinician based on the patient’s condition, treatment phase, and clinical guidelines. Typical regimens involve a once‑daily oral dose, but the exact amount and duration are individualized and should follow the prescriber’s instructions.

Letrozol Aristo is contraindicated in pregnancy because it can harm a developing fetus. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant. Women of child‑bearing potential should use effective contraception while on therapy.

To order Letrozol Aristo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Letrozol Aristo (letrozole) is a third‑generation aromatase inhibitor with a long half‑life and potent estrogen suppression, similar to anastrozole and exemestane. Compared with anastrozole, letrozole often provides slightly greater estrogen reduction, while exemestane is a steroidal inhibitor with a different safety profile.

Letrozol Aristo should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Letrozol Aristo is taken orally, usually as a whole tablet swallowed with water. It is generally administered once daily, with or without food, as directed by the prescriber. Patients should follow the dosing schedule precisely and not alter the regimen without medical advice.

Serious risks include severe liver injury, osteoporotic fractures due to bone loss, cardiovascular events such as myocardial infarction or pulmonary embolism, and rare allergic reactions like anaphylaxis. Patients should report symptoms such as jaundice, sudden bone pain, chest discomfort, or severe rash to their healthcare provider promptly.

Letrozol Aristo should not be used in premenopausal women, patients with known hypersensitivity to letrozole or other aromatase inhibitors, and individuals with severe liver impairment. It is also contraindicated during pregnancy and is generally avoided in patients with uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT